Hermansen Johanne U, Yin Yanping, Rein Idun Dale, Skånland Sigrid S
Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
K. G. Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
NPJ Precis Oncol. 2024 May 20;8(1):107. doi: 10.1038/s41698-024-00604-y.
The microenvironment of hematologic cancers contributes to tumor cell survival and proliferation, as well as treatment resistance. Understanding tumor- and drug-induced changes to the immune cell composition and functionality is therefore critical for implementing optimal treatment strategies and for the development of novel cancer therapies. The liquid nature of peripheral blood makes this organ uniquely suited for single-cell studies by flow cytometry. (Phospho)protein profiles detected by flow cytometry analyses have been shown to correlate with ex vivo drug sensitivity and to predict treatment outcomes in hematologic cancers, demonstrating that this method is suitable for pre-clinical studies. Here, we present a flow cytometry protocol that combines multi-parameter immunophenotyping with single-cell (phospho)protein profiling. The protocol makes use of fluorescent cell barcoding, which means that multiple cell samples, either collected from different donors or exposed to different treatment conditions, can be combined and analyzed as one experiment. This reduces variability between samples, increases the throughput of the experiment, and lowers experimental costs. This protocol may serve as a guide for the use and further development of assays to study immunophenotype and cell signaling at single-cell resolution in normal and malignant cells. The read-outs may provide biological insight into cancer pathogenesis, identify novel drug targets, and ultimately serve as a biomarker to guide clinical decision-making.
血液系统癌症的微环境有助于肿瘤细胞的存活和增殖,以及导致治疗耐药性。因此,了解肿瘤和药物诱导的免疫细胞组成及功能变化对于实施最佳治疗策略和开发新型癌症疗法至关重要。外周血的液态性质使其成为通过流式细胞术进行单细胞研究的独特理想器官。流式细胞术分析检测到的(磷酸化)蛋白质谱已被证明与体外药物敏感性相关,并可预测血液系统癌症的治疗结果,表明该方法适用于临床前研究。在此,我们展示了一种流式细胞术方案,该方案将多参数免疫表型分析与单细胞(磷酸化)蛋白质分析相结合。该方案利用荧光细胞条形码技术,这意味着从不同供体收集的或暴露于不同治疗条件下的多个细胞样本可以合并并作为一个实验进行分析。这减少了样本间的变异性,提高了实验通量,并降低了实验成本。该方案可作为在正常细胞和恶性细胞中以单细胞分辨率研究免疫表型和细胞信号传导的检测方法的使用和进一步开发指南。这些检测结果可能为癌症发病机制提供生物学见解,识别新的药物靶点,并最终作为指导临床决策的生物标志物。